http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yoshihide Toyoshima,Masanori Okuyama,Minoru Noda,Mitsue Takahashi 한국물리학회 2003 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.42 No.IV
SrBi2Ta2O9-Bi2SiO5 (SBT-BSO) thin lms have been prepared on Pt/Ti/SiO2/Si substrate by pulsed laser deposition at low temperature, 300 to 450 C . We succeeded in crystallizing SBT at 350 C and P-E hysterisis loops of SBT-BSO thin lm were observed and the curve was almost the same as that of SBT. Binding state of BSO has been investigated by XPS spectra, Raman spectra and AFM. As a result it is conrmed that the binding state of BSO in ceramics is dierent from that in lms prepared by PLD. Moreover we tried to anneal SBT and SBT-BSO thin lms in high pressure O2 atmosphere, and succeeded in improve ferroelectric properties about SBT.
Noda, Minoru,Kodama, Kazushi,Kitai, Satoshi,Takahashi, Mitsue,Kanashima, Takeshi,Okuyama, Masanori The Korean Institute of Electrical and Electronic 2003 전기전자재료 Vol.16 No.9
A metal-ferroelectric [SrBi$_2$Ta$_2$O$\_$9/ (SBT)-high-k-insulator(PrOx)-semiconductor(Si) structure has been fabricated and evaluated as a key part of metal-ferroelectric-insulator-semiconductor-field-effect-transistor MFIS-FET memory, aiming to improve the memory retention characteristics by increasing the dielectric constant in the insulator layer and suppressing the depolarization field in the SBT layer. A 20-nm PrOx film grown on Si(100) showed both a high of about 12 and a low leakage current density of less than 1${\times}$ 10e-8 A/$\textrm{cm}^2$ at 105 MV/cm. A 400-nm SBT film prepared on PrOx/Si shows a preferentially oriented (105) crystalline structure, grain size of about 130 nm and subface roughness of 3.2 nm. A capacitance-voltage hysteresis is confirmed on the Pt/SBT/PrOx/Si diode with a memory window of 0.3V at a sweep voltage width of 12 V. The memory retention time was about 1 104s, comparable to the conventional Pt/SBT/SiO$\_$x/N$\_$y/(SiO$\_$N/)/Si. The gradual change of the capacitance indicates that some memory degradation mechanism is different from that in the Pt/SBT/SiON/Si structure.
Ohmachi, Ken,Niitsu, Nozomi,Uchida, Toshiki,Kim, Seok Jin,Ando, Kiyoshi,Takahashi, Naoki,Takahashi, Naoto,Uike, Naokuni,Eom, Hyeon Seok,Chae, Yee Soo,Terauchi, Takashi,Tateishi, Ukihide,Tatsumi, Mitsu American Society for Clinical Oncology 2013 Journal of clinical oncology Vol.31 No.17
<P><B>Purpose</B></P><P>Effective and less aggressive therapies are required for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for or have undergone autologous stem-cell transplantation (ASCT). The present phase II study assessed the efficacy and safety of bendamustine plus rituximab (BR) in this population.</P><P><B>Patients and Methods</B></P><P>Patients with relapsed or refractory DLBCL treated with one to three prior chemotherapy regimens received rituximab 375 mg/m<SUP>2</SUP> intravenous (IV) infusion on day 1 and bendamustine 120 mg/m<SUP>2</SUP> by IV infusion on days 2 and 3 of each 21-day cycle for up to six cycles. The primary end point was overall response rate (ORR), and the secondary end points were complete response (CR) rate, progression-free survival (PFS), and safety.</P><P><B>Results</B></P><P>Sixty-three patients were enrolled, and 59 received BR. The median age was 67 years (range, 36 to 75 years), and 62.7% of patients were 65 years of age or older. Fifty-seven patients (96.6%) were previously treated with rituximab-containing chemotherapy. The ORR was 62.7% (95% CI, 49.1% to 75.0%), with a CR rate of 37.3% (95% CI, 25.0% to 50.9%). The ORRs were comparable between patients ≥ 65 years of age and less than 65 years (62.2% and 63.6%, respectively). The median PFS was 6.7 months (95% CI, 3.6 to 13.7 months). The most frequently observed grade 3 or 4 adverse events were hematologic: lymphopenia (78.0%), neutropenia (76.3%), leukopenia (72.9%), CD4 lymphopenia (66.1%), and thrombocytopenia (22.0%).</P><P><B>Conclusion</B></P><P>BR is a promising salvage regimen for patients with relapsed or refractory DLBCL after rituximab-containing chemotherapy, warranting further investigation.</P>